Cocaine Use Disorder - Epidemiology Forecast - 2032

Cocaine Use Disorder - Epidemiology Forecast - 2032

DelveInsight’s ‘Cocaine Use Disorder (CUD) - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Cocaine Use Disorder, historical and forecasted epidemiology as well as the Cocaine Use Disorder trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cocaine Use Disorder Understanding

Cocaine Use Disorder is a severe public health problem, affecting millions of people globally caused by the compulsive use of cocaine despite its medical, psychological, and behavioral consequences. This devastating disorder impacts both individuals and society. Short-term cocaine use begins to show signs of mental alertness, extreme happiness, and energy, hypersensitivity to sight, sound, touch, and irritability. Other health effects of cocaine are dilated pupils, constricted blood vessels, nausea, restlessness, and raised body temperature

It is associated with comorbidities, such as anxiety, depression, and fatigue, which significantly impact the quality of life. Cocaine use leads to increased levels of the natural chemical messenger dopamine in the brain circuits that controls movement and reward. Usually, dopamine is recycled back into the cell that released it, shutting off the signals between nerve cells. Cocaine prevents this dopamine from being re-cycled and causes a large amount to build up in the space between nerve cells thus, stopping their normal communication.

Cocaine Use Disorder Diagnosis

According to the DSM-5 definition, CUD is significant impairment and distress caused by at least 2 of 11 criteria in the preceding 12 months. The 11 criteria can be organized into the following 4 groups: 1) physiologic, including craving, tolerance, and withdrawal, 2) loss of control of cocaine use, 3) cocaine use taking precedence over other activities (including responsibilities at home, work, or school), and 4) other negative consequences from cocaine use. According to the DSM, the presence of two or three symptoms indicates mild CUD, the presence of four or five symptoms indicates moderate CUD, and the presence of six or more symptoms indicates severe CUD.

Continued in the report…..

Cocaine Use Disorder Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by 12-month Diagnosed prevalent cases of Cocaine Use Disorder, Gender-specific cases of Cocaine Use Disorder, Severity-specific cases of Cocaine Use Disorder, and Age-specific cases of Cocaine Use Disorder in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Cocaine Use Disorder Detailed Epidemiology Segmentation

In 2022, the 12-month diagnosed prevalent cases of Cocaine Use Disorder were estimated to be approximately 1,869,555 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019–2032).

Among the 7MM, the United States accounted for approximately 62% of the total 12-month diagnosed cases of Cocaine Use Disorder in the 7MM in the year 2022 which is expected to increase further during the study period (2019–2032).

In EU4 and the UK, males diagnosed with Cocaine Use Disorder are higher in number than females. In 2022, the cases of Cocaine Use Disorder among males in EU4 and the UK were reported to be approximately 428,220 while among the female population, there were around 186,509 cases of Cocaine Use Disorder. These numbers are expected to rise during the study period (2019–2032).

In 2022, there were approximately 40,725 moderate-severe cases of Cocaine Use Disorder, and approximately 61,342 mild cases of Cocaine Use Disorder in Japan, which are expected to decrease during the study period (2019–2032).

In 2022, there were approximately 6,152 cases of Cocaine Use Disorder in teens of age group 12-17 in the UK, followed by approximately 85,699 cases of Cocaine Use Disorder in adults of age group 18-34, and approximately 95,142 cases of Cocaine Use Disorder among =35year age group people in the UK.

Scope of the Report

The report covers a descriptive overview of Cocaine Use Disorder, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.

The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The report assesses the disease risk and burden of Cocaine Use Disorder.

The report helps to recognize the growth opportunities in the 7MM concerning the patient population.

The report provides the segmentation of the disease epidemiology for the 7MM, 12-month Diagnosed prevalent cases of Cocaine Use Disorder, Gender-specific cases of Cocaine Use Disorder, Severity-specific cases of Cocaine Use Disorder, and Age-specific cases of Cocaine Use Disorder.

Report Highlights

10-Year Forecast of Cocaine Use Disorder

The 7MM coverage

12-month Diagnosed prevalent cases of Cocaine Use Disorder

Gender-specific cases of Cocaine Use Disorder

Severity-specific cases of Cocaine Use Disorder

Age-specific cases of Cocaine Use Disorder

Key Questions Answered

What are the disease risk and burdens of Cocaine Use Disorder?

What is the historical Cocaine Use Disorder patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

What would be the forecasted patient pool of Cocaine Use Disorder at the 7MM level?

What will be the growth opportunities across the 7MM concerning the patient population with Cocaine Use Disorder?

Out of the above-mentioned countries, which country would have the highest prevalent population of Cocaine Use Disorder during the forecast period (2023–2032)?

At what CAGR the population is expected to grow across the 7MM during the forecast period (2023–2032)?

Reasons to buy

The Cocaine Use Disorder report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the 7MM Cocaine Use Disorder epidemiology forecast.

The Cocaine Use Disorder epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.

The Cocaine Use Disorder epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

Patient Segmentation

Disease Risk and Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

Geographies Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2019–2032


1. Key Insights
2. Report Introduction
3. CUD Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of CUD in 2019
3.2. Patient Share (%) Distribution of CUD in 2032
4. Methodology of CUD Epidemiology
5. Executive Summary of CUD
6. Disease Background and Overview of CUD
6.1. Introduction to CUD
6.2. Signs and Symptoms
6.3. DSM 5 criteria for cocaine use disorder: signs and symptoms of CUD
6.4. Classification of CUD
6.5. Etiology
6.6. Risk Factors
6.7. Pathophysiology
6.7.1. Dopamine brain rewarding mechanism
6.7.2. Disruption of serotonin levels at the ventral pallidum
6.7.3. Cholinergic pathway
6.8. Complications of Cocaine Use
6.9. Diagnosis
6.9.1. Key diagnostic factors
6.9.2. Other Diagnostic factors
6.9.3. Diagnostic tests
6.9.4. DSM-5 diagnostic criteria for CUD
6.9.5. DSM-5 diagnostic criteria for diagnosing and classifying substance use disorders
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: The 7MM
7.2.1. Diagnosed Prevalent Cases of CUD
7.2.2. Gender-specific Cases of CUD
7.2.3. Age-specific Cases of CUD
7.2.4. Severity-specific Cases of CUD
7.3. Total 12-month diagnosed prevalent cases of CUD in the 7MM
7.4. The United States
7.4.1. Total 12-month diagnosed prevalent cases of CUD in the US
7.4.2. Gender-specific cases of CUD in the US
7.4.3. Age-specific cases of CUD in the US
7.4.4. Severity-specific cases of CUD in the US
7.5. EU4 and the UK
7.5.1. Total 12-month diagnosed prevalent cases of CUD in EU4 and the UK
7.5.2. Gender-specific cases of CUD in EU4 and the UK
7.5.3. Age-specific cases of CUD in EU4 and the UK
7.5.4. Severity-specific cases of CUD in EU4 and the UK
7.6. Japan
7.6.1. Total 12-month diagnosed prevalent cases of CUD in Japan
7.6.2. Gender-specific cases of CUD in Japan
7.6.3. Age-specific cases of CUD in Japan
7.6.4. Severity-specific cases of CUD in Japan
8. Patient Journey
9. KOL Opinion Leaders’ Views
10. Appendix
10.1. Bibliography
10.2. Acronyms and Abbreviations
10.3. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings